Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

  • Sarink, Danja
  • Schock, Helena
  • Johnson, Theron
  • Chang-Claude, Jenny
  • Overvad, Kim
  • Olsen, Anja
  • Tjønneland, Anne
  • Arveux, Patrick
  • Fournier, Agnès
  • Kvaskoff, Marina
  • Boeing, Heiner
  • Karakatsani, Anna
  • Trichopoulou, Antonia
  • Vecchia, Carlo La
  • Masala, Giovanni
  • Agnoli, Claudia
  • Panico, Salvatore
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • van Gils, Carla H.
  • Peeters, Petra H. M.
  • Weiderpass, Elisabete
  • Agudo, Antonio
  • Rodríguez Barranco, Miguel
  • Huerta Castaño, José María
  • Ardanaz, Eva
  • Gil, Leire
  • Kaw, Kay Tee
  • Schmidt, Julie A.
  • Dossus, Laure
  • His, Mathilde
  • Aune, Dagfinn
  • Riboli, Elio
  • Kaaks, Rudolf
  • Fortner, Renée T.
Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis. Methods: Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models. Results: Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis. Conclusions: High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort

  • Fortner, Renée T.
  • Hüsing, Anika
  • Kühn, Tilman
  • Konar, Meric
  • Overvad, Kim
  • Tjønneland, Anne
  • Hansen, Louise
  • Boutron-Ruault, Marie-Christine
  • Severi, Gianluca
  • Fournier, Agnès
  • Boeing, Heiner
  • Trichopoulou, Antonia
  • Benetou, Vassiliki
  • Orfanos, Philippos
  • Masala, Giovanna
  • Agnoli, Claudia
  • Mattiello, Amalia
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • Bueno de Mesquita, H. Bas
  • Peeters, Petra H. M.
  • Weiderpass, Elisabete
  • Gram, Inger T.
  • Gavrilyuk, Oxana
  • Quirós, José Ramón
  • Huerta Castaño, José María
  • Ardanaz, Eva
  • Larrañaga, Nerea
  • Luján Barroso, Leila
  • Sánchez Cantalejo, Emilio
  • Tunå Butt, Salma
  • Borgquist, Signe
  • Idahl, Annika
  • Lundin, Eva
  • Khaw, Kay-Tee
  • Allen, Naomi E.
  • Rinaldi, Sabina
  • Dossus, Laure
  • Gunter, Marc J.
  • Merritt, Melissa A.
Endometrial cancer risk prediction models including lifestyle, anthropometric and reproductive factors have limited discrimination. Adding biomarker data to these models may improve predictive capacity; to our knowledge, this has not been investigated for endometrial cancer. Using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we investigated the improvement in discrimination gained by adding serum biomarker concentrations to risk estimates derived from an existing risk prediction model based on epidemiologic factors. Serum concentrations of sex steroid hormones, metabolic markers, growth factors, adipokines and cytokines were evaluated in a step-wise backward selection process; biomarkers were retained at p < 0.157 indicating improvement in the Akaike information criterion (AIC). Improvement in discrimination was assessed using the C-statistic for all biomarkers alone, and change in C-statistic from addition of biomarkers to preexisting absolute risk estimates. We used internal validation with bootstrapping (1000-fold) to adjust for over-fitting. Adiponectin, estrone, interleukin-1 receptor antagonist, tumor necrosis factor-alpha and triglycerides were select-ed into the model. After accounting for over-fitting, discrimination was improved by 2.0 percentage points when all evaluated biomarkers were included and 1.7 percentage points in the model including the selected biomarkers. Models including etiologic markers on independent pathways and genetic markers may further improve discrimination.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

  • Fortner, Renée T.
  • Sarink, Danja
  • Schock, Helena
  • Johnson, Theron
  • Tjønneland, Anne
  • Olsen, Anja
  • Overvad, Kim
  • Affret, Aurélie
  • His, Mathilde
  • Boutron-Ruault, Marie-Christine
  • Boeing, Heiner
  • Trichopoulou, Antonia
  • Naska, Androniki
  • Orfanos, Philippos
  • Palli, Domenico
  • Sieri, Sabina
  • Mattiello, Amalia
  • Tumino, Rosario
  • Ricceri, Fulvio
  • Bueno de Mesquita, H. Bas
  • Peeters, Petra H. M.
  • van Gils, Carla H.
  • Weiderpass, Elisabete
  • Lund, Eiliv
  • Quirós, José Ramón
  • Agudo, Antonio
  • Sánchez, María José
  • Chirlaque, María Dolores
  • Ardanaz, Eva
  • Dorronsoro, Miren
  • Key, Timothy J.
  • Khaw, Kay-Tee
  • Rinaldi, Sabina
  • Dossus, Laure
  • Gunter, Marc J.
  • Merritt, Melissa A.
  • Riboli, Elio
  • Kaaks, Rudolf
Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1: 1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER-breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER-breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p(trend) = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER-disease did not differ by menopausal status at blood collection (p(het) = 0.97), and we observed no heterogeneity by HT use at blood collection (p(het) >= 0.43) or age at breast cancer diagnosis (p(het) >= 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER-breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

  • Fortner, Renée T.
  • Sarink, Danja
  • Schock, Helena
  • Johnson, Theron
  • Tjønneland, Anne
  • Olsen, Anja
  • Overvad, Kim
  • Affret, Aurélie
  • His, Mathilde
  • Boutron-Ruault, Marie-Christine
  • Boeing, Heiner
  • Trichopoulou, Antonia
  • Naska, Androniki
  • Orfanos, Philippos
  • Palli, Domenico
  • Sieri, Sabina
  • Mattiello, Amalia
  • Tumino, Rosario
  • Ricceri, Fulvio
  • Bueno de Mesquita, H. Bas
  • Peeters, Petra H. M.
  • van Gils, Carla H.
  • Weiderpass, Elisabete
  • Lund, Eiliv
  • Quirós, José Ramón
  • Agudo, Antonio
  • Sánchez, María José
  • Chirlaque, María Dolores
  • Ardanaz, Eva
  • Dorronsoro, Miren
  • Key, Timothy J.
  • Khaw, Kay-Tee
  • Rinaldi, Sabina
  • Dossus, Laure
  • Gunter, Marc J.
  • Merritt, Melissa A.
  • Riboli, Elio
  • Kaaks, Rudolf
Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1: 1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER-breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER-breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p(trend) = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER-disease did not differ by menopausal status at blood collection (p(het) = 0.97), and we observed no heterogeneity by HT use at blood collection (p(het) >= 0.43) or age at breast cancer diagnosis (p(het) >= 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER-breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

  • Sarink, Danja
  • Schock, Helena
  • Johnson, Theron
  • Chang-Claude, Jenny
  • Overvad, Kim
  • Olsen, Anja
  • Tjønneland, Anne
  • Arveux, Patrick
  • Fournier, Agnès
  • Kvaskoff, Marina
  • Boeing, Heiner
  • Karakatsani, Anna
  • Trichopoulou, Antonia
  • Vecchia, Carlo La
  • Masala, Giovanni
  • Agnoli, Claudia
  • Panico, Salvatore
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • van Gils, Carla H.
  • Peeters, Petra H. M.
  • Weiderpass, Elisabete
  • Agudo, Antonio
  • Rodríguez Barranco, Miguel
  • Huerta Castaño, José María
  • Ardanaz, Eva
  • Gil, Leire
  • Kaw, Kay Tee
  • Schmidt, Julie A.
  • Dossus, Laure
  • His, Mathilde
  • Aune, Dagfinn
  • Riboli, Elio
  • Kaaks, Rudolf
  • Fortner, Renée T.
Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis. Methods: Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81%) with ER+ disease) participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed-up for mortality. Pre-diagnosis concentrations of sRANKL and OPG were quantified in baseline serum samples using an enzyme-linked immunosorbent assay and electrochemiluminescent assay, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer-specific and overall mortality were calculated using Cox proportional hazards regression models. Results: Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific (quintile 5 vs 1 HR 1.77 [CI 1.03, 3.04]; ptrend 0.10) and overall mortality (q5 vs 1 HR 1.39 [CI 0.94, 2.05]; ptrend 0.02). sRANKL and the sRANKL/OPG ratio were not associated with mortality following a breast cancer diagnosis. Conclusions: High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease. These results need to be confirmed in well-characterized patient cohorts.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Endometrial cancer risk prediction including serum-based biomarkers: results from the EPIC cohort

  • Fortner, Renée T.
  • Hüsing, Anika
  • Kühn, Tilman
  • Konar, Meric
  • Overvad, Kim
  • Tjønneland, Anne
  • Hansen, Louise
  • Boutron-Ruault, Marie-Christine
  • Severi, Gianluca
  • Fournier, Agnès
  • Boeing, Heiner
  • Trichopoulou, Antonia
  • Benetou, Vassiliki
  • Orfanos, Philippos
  • Masala, Giovanna
  • Agnoli, Claudia
  • Mattiello, Amalia
  • Tumino, Rosario
  • Sacerdote, Carlotta
  • Bueno de Mesquita, H. Bas
  • Peeters, Petra H. M.
  • Weiderpass, Elisabete
  • Gram, Inger T.
  • Gavrilyuk, Oxana
  • Quirós, José Ramón
  • Huerta Castaño, José María
  • Ardanaz, Eva
  • Larrañaga, Nerea
  • Luján Barroso, Leila
  • Sánchez Cantalejo, Emilio
  • Tunå Butt, Salma
  • Borgquist, Signe
  • Idahl, Annika
  • Lundin, Eva
  • Khaw, Kay-Tee
  • Allen, Naomi E.
  • Rinaldi, Sabina
  • Dossus, Laure
  • Gunter, Marc J.
  • Merritt, Melissa A.
Endometrial cancer risk prediction models including lifestyle, anthropometric and reproductive factors have limited discrimination. Adding biomarker data to these models may improve predictive capacity; to our knowledge, this has not been investigated for endometrial cancer. Using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we investigated the improvement in discrimination gained by adding serum biomarker concentrations to risk estimates derived from an existing risk prediction model based on epidemiologic factors. Serum concentrations of sex steroid hormones, metabolic markers, growth factors, adipokines and cytokines were evaluated in a step-wise backward selection process; biomarkers were retained at p < 0.157 indicating improvement in the Akaike information criterion (AIC). Improvement in discrimination was assessed using the C-statistic for all biomarkers alone, and change in C-statistic from addition of biomarkers to preexisting absolute risk estimates. We used internal validation with bootstrapping (1000-fold) to adjust for over-fitting. Adiponectin, estrone, interleukin-1 receptor antagonist, tumor necrosis factor-alpha and triglycerides were select-ed into the model. After accounting for over-fitting, discrimination was improved by 2.0 percentage points when all evaluated biomarkers were included and 1.7 percentage points in the model including the selected biomarkers. Models including etiologic markers on independent pathways and genetic markers may further improve discrimination.